Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Download PDF Copy

May 21 2010

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL. Presentations will highlight data from the carfilzomib development program in patients with relapsed/refractory multiple myeloma and solid tumors. Each presentation will include updated data at the annual meeting that will not be available in the online abstracts at www.asco.org.

"We are further encouraged by the growing body of evidence that supports carfilzomib's potential as a new treatment option for patients with multiple myeloma," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx. "We look forward to sharing final data from our Phase 2b 003-A1 pivotal trial that we anticipate will form the basis of an initial New Drug Application (NDA) filing for carfilzomib by year end."

Carfilzomib data presentations:

Multiple Myeloma

Results of an Ongoing Open-Label, Phase 2 Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Dr. Ravi Vij, Washington University School of Medicine
Saturday, June 5, 2010, 4:30 - 6:00 p.m., E354a
Clinical Science Symposium: Lymphoma and Plasma Cell Disorders
Abstract #8000

Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)

Dr. William Besinger, University of Washington School of Medicine
Friday, June 4, 2010, 8:00 a.m. - 12:00 p.m., S Hall A2
Poster session: Lymphoma and Plasma Cell Disorders
Abstract #8029, poster board 8

Phase 2 Study of Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma and Renal Insufficiency (MM)

Dr. Ashraf Badros, University of Maryland School of Medicine
Saturday, June 5, 2010, 9:00 a.m. - 12:00 p.m., S Hall A2
Poster session: Lymphoma and Plasma Cell Disorders
Abstract #8128, poster board 36F

Neurotoxic and Peripheral Neuropathic Effects in Preclinical and Clinical Studies of Carfilzomib, a Novel Proteasome Inhibitor (PI)

Dr. Jeffrey Wolf, University of California San Francisco Comprehensive Cancer Center
Saturday, June 5, 2010, 8:00 - 12:00 p.m., S Hall A2
Poster session: Lymphoma and Plasma Cell Disorders
Abstract #8135, poster board 37E

Solid Tumors & Multiple Myeloma

Updated Results of a Phase 1b/2 Study of Carfilzomib in Patients with Relapsed Malignancies